NeueHealth price target lowered to $7 from $8 at RBC Capital

RBC Capital analyst Ben Hendrix lowered the firm’s price target on NeueHealth (NEUE) to $7 from $8 and keeps a Sector Perform rating on the shares. The company reported solid Q3 results ahead of expectations and the management maintained guidance, though the firm is reducing its price target as it rolls its valuation out to 2025, the analyst tells investors in a research note.